ID23855A - Protein pengikat osteoprotegerin dan reseptor - Google Patents

Protein pengikat osteoprotegerin dan reseptor

Info

Publication number
ID23855A
ID23855A IDW991225A ID991225A ID23855A ID 23855 A ID23855 A ID 23855A ID W991225 A IDW991225 A ID W991225A ID 991225 A ID991225 A ID 991225A ID 23855 A ID23855 A ID 23855A
Authority
ID
Indonesia
Prior art keywords
fragments
encoding
sequence
nucleic acid
osteoprotegerin
Prior art date
Application number
IDW991225A
Other languages
English (en)
Indonesian (id)
Inventor
William J Boyle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID23855(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/842,842 external-priority patent/US5843678A/en
Priority claimed from US09/052,521 external-priority patent/US6316408B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ID23855A publication Critical patent/ID23855A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IDW991225A 1997-04-16 1998-04-15 Protein pengikat osteoprotegerin dan reseptor ID23855A (id)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/842,842 US5843678A (en) 1997-04-16 1997-04-16 Osteoprotegerin binding proteins
US88085597A 1997-06-23 1997-06-23
US09/052,521 US6316408B1 (en) 1997-04-16 1998-03-30 Methods of use for osetoprotegerin binding protein receptors

Publications (1)

Publication Number Publication Date
ID23855A true ID23855A (id) 2000-05-25

Family

ID=27368158

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991225A ID23855A (id) 1997-04-16 1998-04-15 Protein pengikat osteoprotegerin dan reseptor

Country Status (27)

Country Link
US (1) US7923008B2 (cs)
EP (2) EP1717315A3 (cs)
JP (2) JP2001526532A (cs)
CN (1) CN1264427A (cs)
AT (1) ATE363533T1 (cs)
AU (4) AU743257B2 (cs)
BG (1) BG65242B1 (cs)
BR (1) BR9808545A (cs)
CA (1) CA2285746C (cs)
CZ (1) CZ302262B6 (cs)
DE (1) DE69837845T3 (cs)
DK (1) DK0975754T4 (cs)
EA (1) EA003636B1 (cs)
EE (1) EE05496B1 (cs)
ES (1) ES2284203T5 (cs)
HU (1) HU230547B1 (cs)
ID (1) ID23855A (cs)
IL (1) IL132304A0 (cs)
NO (1) NO325175B1 (cs)
NZ (1) NZ500253A (cs)
PL (1) PL190092B1 (cs)
RO (1) RO128635A2 (cs)
SI (1) SI0975754T2 (cs)
SK (1) SK288559B6 (cs)
TR (1) TR199902512T2 (cs)
TW (1) TW589376B (cs)
WO (1) WO1998046751A1 (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
EP1114864B9 (en) 1996-12-13 2013-05-08 Schering Corporation Mammalian cell surface antigens, related reagents
DE122010000048I1 (de) * 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE122010000049I1 (de) 1997-04-15 2011-05-05 Daiichi Sankyo Co Ltd Neues protein und verfahren zu dessen herstellung
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
EP1076699B1 (en) * 1998-05-14 2008-10-29 Immunex Corporation Method of inhibiting osteoclast activity
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
SI1114166T1 (en) * 1998-09-15 2005-10-31 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
ES2239457T3 (es) 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
ES2279649T3 (es) 1998-10-23 2007-08-16 Amgen Inc. Compuestos trombopoyeticos.
NZ515990A (en) 1999-06-28 2003-10-31 Genentech Inc Methods for making Apo-2 ligand using divalent metal ions
CA2383154C (en) 1999-08-17 2013-04-30 Biogen, Inc. Baff receptor (bcma), an immunoregulatory agent
WO2001023559A1 (en) * 1999-09-27 2001-04-05 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP4401613B2 (ja) * 2000-02-23 2010-01-20 アムジエン・インコーポレーテツド オステオプロテゲリン結合タンパク質のアンタゴニスト性選択的結合因子
US6600018B1 (en) 2000-04-10 2003-07-29 The United States Of America As Represented By The Department Of Health And Human Services Secreted frizzled related protein, sFRP, fragments and methods of use thereof
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP2014303A2 (en) 2000-07-27 2009-01-14 Genentech, Inc. APO-2L receptor agonist and CPT-11 synergism
WO2002016551A2 (en) * 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
PT1387854E (pt) 2001-01-10 2012-06-26 Us Dept Health Sfrp e motivos de peptídeos que interagem com a sfrp e respectivos métodos de utilização
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
NZ616594A (en) * 2001-06-26 2015-06-26 Amgen Inc Antibodies to opgl
AU2002366430B2 (en) 2001-07-03 2008-09-18 Genentech, Inc. Human DR4 antibodies and uses thereof
US20040186051A1 (en) 2001-10-02 2004-09-23 Kelley Robert F Apo-2 ligand variants and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP2332531B1 (en) 2001-11-13 2019-07-10 Genentech, Inc. Methods of purifying Apo2-Ligand/TRAIL
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
AU2011265413B2 (en) * 2002-04-05 2014-04-10 Amgen Inc. Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US20060141561A1 (en) 2002-06-24 2006-06-29 Kelley Robert F Apo-2 ligand/trail variants and uses thereof
EP1578305A4 (en) 2002-12-10 2008-08-27 Schering Plough Ltd CANIN RANKL AND METHODS OF PREPARATION AND USE THEREOF
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
NZ578983A (en) 2004-08-06 2011-03-31 Genentech Inc Assays and methods to detect biomarkers predictive of sensitivity to Apo2L/TRAIL
RU2410438C2 (ru) 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
RU2409817C2 (ru) 2005-08-16 2011-01-20 Дженентек, Инк. Анализы и способы применения биомаркеров
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2008080112A2 (en) * 2006-12-22 2008-07-03 The Regents Of The University Of California New fusion molecule based on novel taa variant
CA2840407A1 (en) 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2008155397A2 (en) * 2007-06-20 2008-12-24 Galapagos N.V. Molecular targets and compounds, and methods to identify the same, useful in the treatment of bone and joint degenerative diseases
CA2695522C (en) * 2008-05-02 2019-01-15 Kyoto University Method of nuclear reprogramming
WO2010062904A2 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
US20150025077A1 (en) 2012-02-29 2015-01-22 Coyote Pharmaceuticals, Inc. Gga and gga derivatives compositions thereof and methods for treating neurodegenerative diseases including paralysis including them
US9119808B1 (en) 2012-10-08 2015-09-01 Coyote Pharmaceuticals, Inc. Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
JP6668241B2 (ja) 2013-09-05 2020-03-18 アムジエン・インコーポレーテツド 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すＦｃ含有分子
EP3467501B1 (en) 2014-05-16 2020-11-04 Amgen Inc. Assay for detecting th1 and th2 cell populations
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
MA47775A (fr) 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MX2020005182A (es) 2017-11-22 2020-08-17 Inbiomotion Sl Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
MA52186A (fr) 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
CN113621060B (zh) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 一种opg抗体对及其应用
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
EP4352094A1 (en) 2021-06-07 2024-04-17 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4710457A (en) 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
PT639079E (pt) 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
DE69427588T2 (de) 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN-TYROSINPHOSPHATASE DECODIERENDE cDNA
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5641747A (en) 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
AU708972B2 (en) * 1994-11-07 1999-08-19 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000318A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
DK0835305T3 (da) * 1995-06-29 2006-02-13 Immunex Corp Cytokin som inducerer apoptose
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6046048A (en) 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US5981220A (en) * 1996-03-27 1999-11-09 Human Genome Sciences, Inc. Epidermal differentiation factor
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP1114864B9 (en) * 1996-12-13 2013-05-08 Schering Corporation Mammalian cell surface antigens, related reagents
AU5901598A (en) 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE122010000048I1 (de) * 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
DE122010000049I1 (de) * 1997-04-15 2011-05-05 Daiichi Sankyo Co Ltd Neues protein und verfahren zu dessen herstellung
ATE363533T1 (de) 1997-04-16 2007-06-15 Amgen Inc Osteoprotegerin bindende proteine und rezeptoren
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP1076699B1 (en) * 1998-05-14 2008-10-29 Immunex Corporation Method of inhibiting osteoclast activity
ES2239457T3 (es) * 1998-09-15 2005-09-16 Pharmexa A/S Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina.
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
EP1800691A3 (en) 1999-09-03 2007-10-31 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
JP4401613B2 (ja) 2000-02-23 2010-01-20 アムジエン・インコーポレーテツド オステオプロテゲリン結合タンパク質のアンタゴニスト性選択的結合因子
WO2002016551A2 (en) 2000-08-18 2002-02-28 University Of Massachusetts Medical Center Trance regulation of chondrocyte differentiation
AU9303001A (en) * 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
MXPA03010531A (es) 2001-05-17 2004-07-01 Immunex Corp Uso terapeutico de antagonistas de rank.
US20030021785A1 (en) * 2001-06-06 2003-01-30 Dougall William C. Use of rank antagonists to treat cancer
NZ616594A (en) 2001-06-26 2015-06-26 Amgen Inc Antibodies to opgl
US6753755B2 (en) * 2001-06-28 2004-06-22 Safer Home, Inc. Electrical safety connector fuse
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) * 2001-12-18 2003-07-15 Kimberly-Clark Worldwide Dispenser for sheet material containing a dispensing port incrementally variable within a range
WO2003086289A2 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7706431B2 (en) * 2005-06-30 2010-04-27 Nokia Corporation System and method for providing optimized receiver architectures for combined pilot and data signal tracking

Also Published As

Publication number Publication date
JP2001526532A (ja) 2001-12-18
BR9808545A (pt) 2000-05-23
BG103824A (en) 2000-05-31
NO995044D0 (no) 1999-10-15
HK1022330A1 (en) 2000-08-04
AU779461B2 (en) 2005-01-27
CA2285746A1 (en) 1998-10-22
ES2284203T3 (es) 2007-11-01
EP1717315A2 (en) 2006-11-02
EE05496B1 (et) 2011-12-15
EA003636B1 (ru) 2003-08-28
SI0975754T2 (sl) 2016-04-29
EP0975754B1 (en) 2007-05-30
EA199900939A1 (ru) 2000-08-28
DK0975754T4 (en) 2016-03-21
SK141999A3 (en) 2000-05-16
EE9900611A (et) 2000-08-15
HUP0001400A2 (en) 2000-07-28
PL336311A1 (en) 2000-06-19
CA2285746C (en) 2010-09-28
EP0975754A1 (en) 2000-02-02
AU779461C (en) 2005-10-13
DE69837845T2 (de) 2008-01-31
US20060246064A1 (en) 2006-11-02
AU9523401A (en) 2002-01-24
NO995044L (no) 1999-12-15
ATE363533T1 (de) 2007-06-15
EP0975754B2 (en) 2016-01-06
SK288559B6 (sk) 2018-05-02
US7923008B2 (en) 2011-04-12
DE69837845T3 (de) 2016-06-23
TR199902512T2 (xx) 2000-06-21
HUP0001400A3 (en) 2001-12-28
AU743257B2 (en) 2002-01-24
DE69837845D1 (de) 2007-07-12
CZ359899A3 (cs) 2000-02-16
AU2005201799A1 (en) 2005-05-26
TW589376B (en) 2004-06-01
CZ302262B6 (cs) 2011-01-19
AU7120598A (en) 1998-11-11
NZ500253A (en) 2002-09-27
SI0975754T1 (sl) 2007-10-31
IL132304A0 (en) 2001-03-19
DK0975754T3 (da) 2007-10-01
JP5001758B2 (ja) 2012-08-15
WO1998046751A1 (en) 1998-10-22
ES2284203T5 (es) 2016-03-11
HU230547B1 (hu) 2016-11-28
CN1264427A (zh) 2000-08-23
PL190092B1 (pl) 2005-10-31
NO325175B1 (no) 2008-02-11
BG65242B1 (bg) 2007-09-28
RO128635A2 (ro) 2013-07-30
JP2008054682A (ja) 2008-03-13
AU2005201799B2 (en) 2008-06-12
AU2008202516A1 (en) 2008-06-26
EP1717315A3 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
ID23855A (id) Protein pengikat osteoprotegerin dan reseptor
DE69535641D1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
ATE283916T1 (de) Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
DE69406423D1 (de) Methode zum überbringen von agenzien an zielzellen
BR9814335A (pt) Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
PT2305715T (pt) Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
AU735355C (en) Novel protein and method for producing the protein
BRPI9809391B8 (pt) processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
WO1995009872B1 (en) Dna encoding prostaglandin receptor ip
DE69738370D1 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
BR9407512A (pt) Sequência de ácidos nucléicos vírus recombinante defectivo vetor notadamente virale composição farmaceutica e utilização de uma sequencia de ácidos nucléicos
BR9811861A (pt) Polipeptìdeos de fatores de crescimento ligantes de heparina (fclh)
WO1997007135A3 (en) Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
ATE426028T1 (de) Zellvolumenregulierte humane kinase h-sgk
KR870001311A (ko) 단백질 및 폴리펩티드의 제조 방법
BR0013043A (pt) Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO2000001820A3 (en) Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof
Greenblatt et al. Properties of the N gene transcription antitermination protein of bacteriophage lambda.
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
GEP20002244B (en) Osteoprotegerin